Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (July 12th Preview)
-
Regulatory setbacks in neurodegeneration and manufacturing
Roche discontinued two Huntington’s disease antisense programs with Ionis—halting the Phase 2 GENERATION HD2 study of tominersen after it failed a key efficacy objective and stopping a separate trial of RG6496 after new data from a parallel animal study. Roche cited the “totality of data,” with a company spokesperson describing the outcome as “deeply disappointing.” The decision follows earlier trouble for tominersen: Roche previously suspended an early-stage study after catheter-related infections and ended the Phase 3 GENERATION HD1 trial after a pre-planned benefit/risk review. Roche and Ionis said they will continue working on other programs. Separately, the FDA rejected the Hengrui-Elevar liver cancer drug combination for the third time in about two years, citing manufacturing deficiencies. The repeat refusal underscores how supply-chain and process issues can become decisive even when clinical rationale is established.
-
FDA changes to complete response letter cadence
The FDA resumed issuing complete response letters (CRLs), posting 14 new rejection letters after a pause linked to calls for greater transparency. The move comes after HHS confirmed to Endpoints News that the agency had paused new CRL releases. For biopharma developers, the resumption is a practical signal for timelines: CRLs can reset regulatory expectations and force additional work on manufacturing, labeling, or clinical data packages. The new batch includes camrelizumab plus rivoceranib from Hengrui and Elevar, highlighting continued scrutiny on complex oncology regimens. While the content of each CRL batch varies, the agency’s stated rationale centers on process—an attempt to normalize throughput while maintaining a clearer public record of decisions.
-
AI operating model debate for biopharma R&D
McKinsey argued that biopharma companies need “structural redesign” to get full value from AI in drug development, warning that incremental workflow efficiency won’t create “compound learning.” The consultancy’s report says AI can speed decisions, but programs often still run through linear stage gates without closed-loop feedback that drives systematic improvement. McKinsey proposed reorganizing around five connected decision points—from understanding patients and disease biology to improving the real-world impact of approved therapies. The analysis frames the closed-loop R&D model as the mechanism for continuous learning, not just automation of existing steps. The report contrasts traditional operating models with tech-driven approaches already used by some AI-first companies, including closed-loop platform descriptions from firms such as Recursion Pharmaceuticals.
-
Clinical validation for colorectal cancer screening blood test
Freenome’s updated SimpleScreen CRC blood test met primary and secondary endpoints in a clinical validation study, with stakeholders reacting as mixed due to trade-offs in sensitivity details. The study analyzed blinded, previously unevaluated samples from the prospective PREEMPT CRC study plus previously tested specimens. Among more than 48,995 asymptomatic, average-risk adults scheduled for colonoscopy across 200+ sites, the company reported overall sensitivity of 80.4%. Sensitivity for advanced precancerous lesions was 41.9%, and the test detected 100% of stage IV cancers and 97.3% of stage III cancers, according to the company. Freenome said results were adjusted to reflect the intended US population, and that its update would translate to incremental screening benefit versus the prior version, including more cancer deaths prevented and additional life-years gained. CEO Aaron Elliott emphasized improved detection of precancerous lesions.
-
Biomarker advances in Parkinson’s disease progression
Researchers identified plasma phosphorylated tau biomarkers—pTau217 and pTau231—that forecast dementia progression in patients with Parkinson’s disease. The prospective longitudinal work aims to address the lack of reliable early indicators of cognitive decline in Parkinson’s. The study positions blood-based pTau assays as potential tools to stratify risk over time, moving dementia prognostication beyond clinical observation alone. If validated across broader cohorts, such biomarkers could influence trial enrichment and monitoring strategies in Parkinson’s disease. The reported findings come as PD management increasingly emphasizes early detection of neurodegenerative trajectories, including separate efforts to improve home and real-world monitoring approaches.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.